(NASDAQ: AGIO) Agios Pharmaceuticals's forecast annual revenue growth rate of 80.64% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 109.19%, and while it is forecast to beat the US market's average forecast revenue growth rate of 26.12%.
Agios Pharmaceuticals's revenue in 2025 is $44,791,000.On average, 10 Wall Street analysts forecast AGIO's revenue for 2025 to be $2,672,522,004, with the lowest AGIO revenue forecast at $2,285,901,430, and the highest AGIO revenue forecast at $2,914,524,324. On average, 10 Wall Street analysts forecast AGIO's revenue for 2026 to be $6,767,901,021, with the lowest AGIO revenue forecast at $4,400,360,254, and the highest AGIO revenue forecast at $8,860,200,595.
In 2027, AGIO is forecast to generate $16,401,925,901 in revenue, with the lowest revenue forecast at $9,715,081,079 and the highest revenue forecast at $22,192,487,433.